Mannatech earnings
This article was originally published in The Tan Sheet
Executive Summary
Coppell, Texas-based supplement firm's sales increased 56.1% to $77.6 mil. with earnings up 136% to $6.8 mil. in the third quarter, Mannatech announces Nov. 9. The results mark the firm's eighth consecutive quarter of growth, and include its September entry into the South Korean market and signing of a deal with Australian biotech firm Marinova to make microalgae-derived biotherapeutics (1"The Tan Sheet" Sept. 13, 2004, In Brief)...
You may also be interested in...
Mannatech deal
Coppell, Tex.-based firm enters into exclusive multi-year supply agreement with Marinova, an Australian biotech firm specializing in biotherapeutics derived from the macro algae Undaria pinnatifida (brown seaweed), Mannatech announces. The contract is "part of an ongoing effort to secure the best and most exclusive worldwide sources of natural, plant-synthesized polysaccharide structures," CEO Sam Caster says. Marinova has developed a method of using a sulphate polysaccharide galactofucan sulphate and created "a patent-pending high-molecular weight fucoidan product," according to a release...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.